Modalis Therapeutics Corporation
Modalis Therapeutics Corporation (4883.T) Stock Overview
Explore Modalis Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7.2B
P/E Ratio
-4.50
EPS (TTM)
$-28.57
ROE
-0.58%
4883.T Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Modalis Therapeutics Corporation (4883.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 61.55, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $44.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.50 and a market capitalization of 7.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Haruhiko Morita
14
Y’s Building, Tokyo
2020